Materialise (MTLS) Q2 2026 earnings review
Profitability Surges as Cost Discipline and Medical Growth Pay Off
Materialise delivered a strong first half of 2026, punctuated by an upward revision to full-year Adjusted EBIT guidance. While total H1 revenue grew a stable 3.9% to €136.3M, the real story is operating leverage: tight cost controls and higher-margin Medical sales drove a 71.5% spike in Adjusted EBIT to €6.4M. The company's strategic divestitures of RapidFit and Eyewear have cleanly eliminated non-core distractions, allowing leadership to focus capital on accelerating the Medical segment and executing the Software transition to recurring revenue.
🐂 Bull Case
Management is successfully translating modest revenue growth into outsized profitability gains. Adjusted EBIT guidance for the year was raised, proving that the cost containment and portfolio sharpening strategies are structurally expanding margins.
Medical revenue jumped 9.6% in H1 to €70.0M, generating an elite 29.7% Adjusted EBITDA margin. It remains the undisputed growth engine of the company.
🐻 Bear Case
Software revenue contracted 2.1% in H1, while Manufacturing slipped 1.2%, dragged down by persistent macro weakness in the European automotive and prototyping markets.
Despite raising bottom-line targets, management reaffirmed revenue guidance at €273-€283M. This indicates they do not foresee an immediate macro recovery for the industrial-facing divisions.
⚖️ Verdict: 🟢
Bullish. Materialise is executing a textbook 'control what you can control' strategy. By shedding non-core assets, throttling expenses, and leaning into its highly profitable Medical franchise, the company is driving structural margin expansion even in a weak industrial environment.
Key Themes
Medical Segment Product Innovation Accelerating
The Medical segment remains the crown jewel, growing 9.6% YoY in H1. Growth is being fueled by clear product innovation, notably the launch of OrthoView 3D Hip (shifting from X-ray to CT-based planning) and custom-made PEEK implants. The strategic investment in Replasia further cements their push into early hip preservation. By integrating these tools directly into their existing software ecosystem, Materialise is increasing switching costs for hospitals and surgeons.
Manufacturing Pivot is Reversing the Decline
Reversing the steep declines of 2025, Manufacturing revenue in Q2 2026 implies a ~6.8% YoY growth recovery (€23.6M vs €22.1M in 25Q2). This signals that the strategic shift away from legacy prototyping and toward certified Aerospace and Defense production (e.g., Lufthansa Technik and Airbus Eurodrone contracts) is finally beginning to offset macro headwinds.
Relentless Cost Discipline
The 71.5% spike in H1 Adjusted EBIT was not a top-line phenomenon. It was driven by strict operating expense control and a gross margin expansion to 57.0%. G&A expenses were reduced, allowing more capital to flow to the bottom line despite a sluggish industrial environment.
Software Segment Top-Line Decay
Software segment revenue decelerated, falling 2.1% YoY to €19.2M in H1. While management attributes this to the transition toward a recurring revenue model (CO-AM platform rollout) and FX headwinds, the absolute revenue contraction shows that the aggressive push with products like CO-AM Professional and Magics Print for HP has not yet yielded recognized growth.
Macroeconomic Weakness in European Prototyping
The European industrial and automotive markets remain persistently soft. This macro headwind continues to cap the upside of the legacy prototyping business, forcing Materialise to execute its turnaround largely through cost-cutting rather than volume expansion.
Divestiture Impact and Impairment Charges
To sharpen its focus, Materialise transferred its RapidFit and Eyewear businesses to management teams. While strategically sound, this resulted in a specific non-recurring impairment charge of €0.8M (€67K for RapidFit, €689K for Eyewear) and creates a slight top-line gap that the remaining core business must absorb to meet annual guidance.
Other KPIs
Stable. The company generated €15.1M in operating cash flow while keeping CapEx disciplined at €3.4M. This strong cash generation supported the repurchase of 1.07M shares for €5.2M without compromising the balance sheet, which boasts a €74.2M net cash position.
Accelerating. Up from 10.0% in H1 2025. Despite the 2.1% revenue decline in the segment, tight expense management resulted in a higher segment Adjusted EBITDA of €2.1M, proving that the SaaS transition is improving the quality of earnings.
Guidance
Accelerating. Management explicitly raised this target from the prior €10-€12M range. At the €13M midpoint, this implies robust 23% YoY growth compared to FY25's €10.6M. This demonstrates high confidence in the structural cost savings achieved in H1.
Stable. The guidance range was reaffirmed, implying ~3.7% YoY growth at the midpoint. This conservative stance reflects the ongoing transition in the Software segment and persistent macroeconomic softness in industrial markets.
Key Questions
Software Revenue Inflection Point
With the CO-AM platform fully launched globally in June and the HP partnership ramping up, at what quarter do you expect the Software segment to reverse its revenue contraction and return to positive top-line growth?
Capital Allocation Post-Divestments
Following the divestments of RapidFit and Eyewear, you have an even cleaner balance sheet and €74M in net cash. Beyond the existing buyback program, what are your immediate priorities for M&A, particularly in the Medical or Defense software space?
Defense Sector Materiality
You secured the STRIKE IT project and received orders from Defense exhibitions. When will Defense represent a material percentage of Manufacturing revenue, and how do Defense margins compare to your traditional Aerospace business?